Top

Cancer Chemotherapy and Pharmacology

Published in:

01-09-2015 | Original Article

In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs

Authors: Jia-Xue Yin, Zhi Wei, Jian-Jian Xu, Zi-Qin Sun

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2015

Abstract

Purpose

The aim of this study was to clarify the pharmacokinetic, tissue distribution, hematologic, and histopathologic characteristics of sustained-release cisplatin from implants [CDDP-nanoparticle (NP) implants].

Methods

Eighteen dogs (six hybrids and twelve beagles) were divided into three groups. In Group A, the six hybrid dogs were intravenously administered 20 mg CDDP via a hind limb vein. In Groups B and C, CDDP-NP implants containing CDDP doses of 40 and 60 mg, respectively, were embedded into the esophageal submucosa of beagles via painless gastroscopy with an endoscopic booster. Graphite frameless atomic absorption spectrophotometry was used to measure total platinum in plasma and tissues at various timepoints. In addition, free platinum levels in Group B were determined using inductively coupled plasma mass spectrometry. Toxicologic evaluation was also conducted.

Results

Pharmacokinetic results indicated that the CDDP-NP implant could achieve a smooth pharmacokinetic curve, with the plasma invalid concentration reached after almost 480 h, which is approximately ten times longer than that of standard CDDP (48 h). The peak time, peak concentration, clearance, elimination half-life, area under the curve, volume of distribution at steady state, and mean residence time of Groups B and C were 494 and 211, 0.39 and 0.42, 0.044 and 0.059, 80.11 and 87.70, 44 and 49, 38.8 and 57.9, and 12.29 and 12.39 times those of Group A, respectively (all P < 0.05). The ratio of free/total platinum concentration was 2.0–3.1 % in plasma, 14.2 % in liver tissue, and 14.3 % in kidney tissue. Tissue distribution studies showed that the highest platinum concentrations were found in the esophagus, followed by the kidney and liver. Compared with pre-implantation (day 0), there were no significant differences in most hematological indicators in Groups B and C (P > 0.05). Furthermore, histopathologic examination of the kidneys of dogs from Group C revealed no significant kidney damage. Unlike the intravenous CDDP group (Group A), no animals in the implantation groups showed any clinical signs of toxicity.

Conclusion

CDDP-NP implants can be used to achieve a smooth pharmacokinetic curve and higher drug concentration, as well as a longer mean residence time at the implantation site, with reduced side effects compared with intravenous CDDP.

Kume M, Yasui H, Yoshikawa Y, Horinouchi M, Higashiguchi K, Kobayashi Y, Kuroda D, Hirano T, Hirai M, Nakamura T (2012) Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients. Cancer Chemother Pharmacol 69(6):1537–1544. doi:10.1007/s00280-012-1860-8 CrossRefPubMed

Berglin CE, Pierre PV, Bramer T, Edsman K, Ehrsson H, Eksborg S, Laurell G (2011) Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model. Cancer Chemother Pharmacol 68(6):1547–1556. doi:10.1007/s00280-011-1656-2 CrossRefPubMed

Wang Y, Zhou J, Qiu L, Wang X, Chen L, Liu T, Di W (2014) Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. Biomaterials 35(14):4297–4309. doi:10.1016/j.biomaterials.2014.01.035 CrossRefPubMed

Li Q, Tian Y, Li D, Sun J, Shi D, Fang L, Gao Y, Liu H (2014) The effect of lipocisplatin on cisplatin efficacy and nephrotoxicity in malignant breast cancer treatment. Biomaterials 35(24):6462–6472. doi:10.1016/j.biomaterials.2014.04.023 CrossRefPubMed

Dasari S, Bernard Tchounwou P (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740C:364–378. doi:10.1016/j.ejphar.2014.07.025 CrossRef

Alam N, Khare V, Dubey R, Saneja A, Kushwaha M, Singh G, Sharma N, Chandan B, Gupta PN (2014) Biodegradable polymeric system for cisplatin delivery: development, in vitro characterization and investigation of toxicity profile. Mater Sci Eng C Mater Biol Appl 38:85–93. doi:10.1016/j.msec.2014.01.043 CrossRefPubMed

Xiong Y, Jiang W, Shen Y, Li H, Sun C, Ouahab A, Tu J (2012) A poly(gamma, l-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery. Biomaterials 33(29):7182–7193. doi:10.1016/j.biomaterials.2012.06.071 CrossRefPubMed

Al-Abd AM, Hong KY, Song SC, Kuh HJ (2010) Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. J Control Release 142(1):101–107. doi:10.1016/j.jconrel.2009.10.003 CrossRefPubMed

Hanafy AF, Yousef MI, Mortada SA, Molokhia AM (2014) Assessment of localized therapeutic effect for prolonged release biodegradable implants loaded with 5-fluorouracil on rats with induced liver cancer. J Taibah Univ Med Sci 9(1):14–22. doi:10.1016/j.jtumed.2013.09.011

10.

Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, Jo HG, Park JH, Choi K, Jeong SY, Park RW, Kim IS, Kim K, Kwon IC (2008) Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release 127(1):41–49. doi:10.1016/j.jconrel.2007.12.014 CrossRefPubMed

11.

Oberoi HS, Nukolova NV, Kabanov AV, Bronich TK (2013) Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev 65(13–14):1667–1685. doi:10.1016/j.addr.2013.09.014 PubMedCentralCrossRefPubMed

12.

Gunji S, Obama K, Matsui M, Tabata Y, Sakai Y (2013) A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin. Surgery 154(5):991–999. doi:10.1016/j.surg.2013.04.054 CrossRefPubMed

13.

Shrikhande SS, Jain DS, Athawale RB, Bajaj AN, Goel P, Kamran Z, Nikam Y, Gude R (2015) Evaluation of anti-metastatic potential of Cisplatin polymeric nanocarriers on B16F10 melanoma cells. Saudi Pharm J. doi:10.1016/j.jsps.2014.08.004

14.

Cabral H, Kataoka K (2014) Progress of drug-loaded polymeric micelles into clinical studies. J Control Release 190:465–476. doi:10.1016/j.jconrel.2014.06.042 CrossRefPubMed

15.

Tong R, Gabrielson NP, Fan TM, Cheng J (2012) Polymeric nanomedicines based on poly(lactide) and poly(lactide-co-glycolide). Curr Opin Solid State Mater Sci 16(6):323–332. doi:10.1016/j.cossms.2013.01.001 PubMedCentralCrossRefPubMed

16.

Chao YK, Wen YW, Liu KS, Wang YC, Wang CW, Liu SJ (2015) Biodegradable drug-eluting pellets provide steady and sustainable cisplatin release in the intrapleural cavity: in vivo and in vitro studies. Int J Pharm 484(1–2):38–43. doi:10.1016/j.ijpharm.2015.02.048 CrossRefPubMed

17.

Combest AJ, Roberts PJ, Dillon PM, Sandison K, Hanna SK, Ross C, Habibi S, Zamboni B, Muller M, Brunner M, Sharpless NE, Zamboni WC (2012) Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors. Oncologist 17(10):1303–1316. doi:10.1634/theoncologist.2012-0274 PubMedCentralCrossRefPubMed

18.

Zalba S, Navarro-Blasco I, Moreno D, Garrido MJ (2010) Application of non-aggressive sample preparation and electrothermal atomic absorption spectrometry to quantify platinum in biological matrices after cisplatin nanoparticle administration. Microchem J 96(2):415–421. doi:10.1016/j.microc.2010.07.006 CrossRef

19.

Zhou X, Wang J, Wu J, Yang X, Yung BC, Lee LJ, Lee RJ (2014) Preparation and evaluation of a novel liposomal formulation of cisplatin. Eur J Pharm Sci C 66:90–95. doi:10.1016/j.ejps.2014.10.004 CrossRef

20.

Bishai M, De S, Adhikari B, Banerjee R (2014) A comprehensive study on enhanced characteristics of modified polylactic acid based versatile biopolymer. Eur Polymer J 54:52–61. doi:10.1016/j.eurpolymj.2014.01.027 CrossRef

21.

Zuo Yf GuJ, Qiao Z, Tan H, Cao J, Zhang Y (2015) Effects of dry method esterification of starch on the degradation characteristics of starch/polylactic acid composites. Int J Biol Macromol 72:391–402. doi:10.1016/j.ijbiomac.2014.08.038 CrossRefPubMed

22.

San Román MS, Holgado MJ, Salinas B, Rives V (2013) Drug release from layered double hydroxides and from their polylactic acid (PLA) nanocomposites. Appl Clay Sci 71:1–7. doi:10.1016/j.clay.2012.10.014 CrossRef

23.

Kratz F, Elsadek B (2012) Clinical impact of serum proteins on drug delivery. J Control Release 161(2):429–445. doi:10.1016/j.jconrel.2011.11.028 CrossRefPubMed

24.

Ossipov K, Scaffidi-Domianello YY, Seregina IF, Galanski M, Keppler BK, Timerbaev AR, Bolshov MA (2014) Inductively coupled plasma mass spectrometry for metallodrug development: albumin binding and serum distribution of cytotoxic cis- and trans-isomeric platinum(II) complexes. J Inorg Biochem 137:40–45. doi:10.1016/j.jinorgbio.2014.04.008 CrossRefPubMed

25.

Pierre PV, Wallin I, Eksborg S, Ehrsson H (2011) Quantitative liquid chromatographic determination of intact cisplatin in blood with microwave-assisted post-column derivatization and UV detection. J Pharm Biomed Anal 56(1):126–130. doi:10.1016/j.jpba.2011.04.028 CrossRefPubMed

26.

Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB (2009) Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. Cancer Chemother Pharmacol 64(2):233–241. doi:10.1007/s00280-008-0853-0 CrossRefPubMed

27.

Wang X, Au-Yeung SC, Ho YP (2007) Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats. J Inorg Biochem 101(6):909–917. doi:10.1016/j.jinorgbio.2007.02.007 CrossRefPubMed

28.

Yu H, Tang Z, Zhang D, Song W, Zhang Y, Yang Y, Ahmad Z, Chen X (2014) Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(l-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy. J Control Release. doi:10.1016/j.jconrel.2014.12.022 PubMedCentral

29.

Ernsting MJ, Murakami M, Roy A, Li SD (2013) Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release 172(3):782–794. doi:10.1016/j.jconrel.2013.09.013 PubMedCentralCrossRefPubMed

30.

Longchar A, Prasad SB (2015) Biochemical changes associated with ascorbic acid-cisplatin combination therapeutic efficacy and protective effect on cisplatin-induced toxicity in tumor-bearing mice. Toxicol Rep. doi:10.1016/j.toxrep.2015.01.017

31.

Nasr AY (2014) Protective effect of aged garlic extract against the oxidative stress induced by cisplatin on blood cells parameters and hepatic antioxidant enzymes in rats. Toxicol Rep 1:682–691. doi:10.1016/j.toxrep.2014.09.003 CrossRef

32.

Zirak MR, Rahimian R, Ghazi-Khansari M, Abbasi A, Razmi A, Ejtemaei Mehr S, Mousavizadeh K, Dehpour AR (2014) Tropisetron attenuates cisplatin-induced nephrotoxicity in mice. Eur J Pharmacol 738:222–229. doi:10.1016/j.ejphar.2014.05.050 CrossRefPubMed

33.

McDuffie JE, Sablad M, Ma J, Snook S (2010) Urinary parameters predictive of cisplatin-induced acute renal injury in dogs. Cytokine 52(3):156–162. doi:10.1016/j.cyto.2010.06.005 CrossRefPubMed

Title: In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs
Authors: Jia-Xue Yin
Zhi Wei
Jian-Jian Xu
Zi-Qin Sun
Publication date: 01-09-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-015-2823-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2015

Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis

S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies

A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer

Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients

A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors

Lower antioxidative capacity of multidrug-resistant cancer cells confers collateral sensitivity to protoflavone derivatives

Keynote webinar | Spotlight on antibody–drug conjugates in cancer